Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40FFK | ISIN: US0050831009 | Ticker-Symbol:
NASDAQ
06.06.25 | 22:00
8,960 US-Dollar
-1,43 % -0,130
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACTUATE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ACTUATE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur ACTUATE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoASCO: Actuate's pancreatic cancer drug boosts survival by 3 months in phase 2 study3
MoACTUATE THERAPEUTICS, INC. - 8-K, Current Report2
SoActuate Therapeutics, Inc. (ACTU)'s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer2
ACTUATE THERAPEUTICS Aktie jetzt für 0€ handeln
31.05.Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer2
31.05.Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic ...48Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously...
► Artikel lesen
23.05.ACTUATE THERAPEUTICS, INC. - 8-K, Current Report4
22.05.Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer2
15.05.ACTUATE THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans2
06.05.ACTUATE THERAPEUTICS, INC. - 8-K, Current Report2
23.04.Actuate Therapeutics: Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting1
22.04.Craig-Hallum sets $21 target on Actuate Therapeutics stock1
17.04.Actuate Therapeutics: Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 20251
13.03.ACTUATE THERAPEUTICS, INC. - 10-K, Annual Report1
25.02.Actuate meldet Fortschritte bei Bauchspeicheldrüsenkrebs-Studie2
07.02.ACTUATE THERAPEUTICS, INC. - 8-K, Current Report-
08.01.EMA gives OMPD to Actuate's pancreatic cancer therapy5
17.12.24ACTUATE THERAPEUTICS, INC. - 8-K, Current Report-
17.12.24Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer174Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year Survival Rate and 37% Reduction in Risk of Death Two Month (29%) Increase in...
► Artikel lesen
17.12.24Actuate reports breakthrough in pancreatic cancer trial1
11.09.24Actuate Therapeutics: Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas363Elraglusib is a Class-Leading GSK-3ß Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer TrialsOrphan Drug Designation in Soft Tissue Sarcomas Expands Company's Potential...
► Artikel lesen
Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1